• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.种间尺度转换与人体清除率预测:小分子药物与大分子药物的比较
Xenobiotica. 2011 Nov;41(11):972-87. doi: 10.3109/00498254.2011.598582. Epub 2011 Sep 5.
2
Interspecies scaling of biliary excreted drugs: a comparison of several methods.胆汁排泄药物的种间剂量换算:几种方法的比较
J Pharm Sci. 2005 Apr;94(4):883-92. doi: 10.1002/jps.20313.
3
Interspecies scaling of biliary excreted drugs: prediction of human clearance and volume of distribution.胆汁排泄药物的种间缩放:人体清除率和分布容积的预测
Drug Metabol Drug Interact. 2012;27(3):157-64. doi: 10.1515/dmdi-2012-0012.
4
Interspecies scaling of protein drugs: prediction of clearance from animals to humans.蛋白质药物的种间剂量换算:从动物到人类的清除率预测
J Pharm Sci. 2004 Jan;93(1):177-85. doi: 10.1002/jps.10531.
5
Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development.小分子和生物制品的毒代动力学评估与种间药代动力学标度方法对比:对生物类似药研发的适用性
Xenobiotica. 2013 Jun;43(6):561-9. doi: 10.3109/00498254.2012.744113. Epub 2012 Dec 17.
6
Interspecies scaling of biliary excreted drugs.经胆汁排泄药物的种间剂量换算
J Pharm Sci. 2002 Aug;91(8):1908-14. doi: 10.1002/jps.10174.
7
Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.应用比例模型法改善人体口服给药后的血药峰浓度、分布容积和半衰期的预测。
Clin Pharmacokinet. 2011 May;50(5):307-18. doi: 10.2165/11539250-000000000-00000.
8
Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.人类代谢药物清除率的预测:体外-体内外推法与异速生长标度法
Xenobiotica. 2006 Jul;36(7):567-80. doi: 10.1080/00498250600761662.
9
Prediction of human drug clearance from two species: a comparison of several allometric methods.从两种物种预测人体药物清除率:几种比例预测法的比较。
J Pharm Sci. 2010 Mar;99(3):1601-13. doi: 10.1002/jps.21926.
10
Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.儿童抗疟药物清除率的预测:三种不同种间缩放方法的比较
Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):767-775. doi: 10.1007/s13318-015-0305-2.

引用本文的文献

1
Fraction-based Linear Extrapolation (FLEX) Method for Predicting Human Pharmacokinetic Clearance: Advanced Allometric Scaling Method and Machine Learning Approach.基于分数的线性外推法(FLEX)预测人体药代动力学清除率:先进的异速生长标度法和机器学习方法
Pharm Res. 2025 Sep 10. doi: 10.1007/s11095-025-03922-3.
2
Species-Dependent Metabolism of a Covalent nsP2 Protease Inhibitor with In Vivo Antialphaviral Activity.具有体内抗α病毒活性的共价nsP2蛋白酶抑制剂的种属依赖性代谢
J Med Chem. 2025 May 22;68(10):10473-10485. doi: 10.1021/acs.jmedchem.5c00825. Epub 2025 May 12.
3
Integrating Pharmacokinetics and Quantitative Systems Pharmacology Approaches in Generative Drug Design.在生成式药物设计中整合药代动力学和定量系统药理学方法。
J Chem Inf Model. 2025 May 26;65(10):4783-4796. doi: 10.1021/acs.jcim.5c00107. Epub 2025 May 9.
4
Prediction of first-in-human dose for new composition bee venom based on allometric scaling and pharmacokinetic modeling approach.基于异速生长比例法和药代动力学建模方法预测新型蜂毒成分的首次人体剂量。
Transl Clin Pharmacol. 2025 Mar;33(1):27-39. doi: 10.12793/tcp.2025.33.e4. Epub 2025 Mar 24.
5
Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis.经鼻脑途径给予 C57BL/6J 小鼠芬戈莫德鼻用膜的药代动力学研究,作为多发性硬化症的潜在治疗方法。
Pharm Res. 2024 Oct;41(10):1951-1963. doi: 10.1007/s11095-024-03745-8. Epub 2024 Oct 29.
6
Active CNS delivery of oxycodone in healthy and endotoxemic pigs.健康猪和内毒素血症猪中枢神经系统中羟考酮的主动递送。
Fluids Barriers CNS. 2024 Oct 23;21(1):86. doi: 10.1186/s12987-024-00583-z.
7
An Evaluation of First-in-Human Studies for RNA Oligonucleotides.RNA寡核苷酸首次人体研究的评估
Nucleic Acid Ther. 2024 Dec;34(6):276-284. doi: 10.1089/nat.2024.0036. Epub 2024 Sep 23.
8
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials.基于生理学的纳米材料药代动力学(PBPK)建模进展。
ACS Pharmacol Transl Sci. 2024 Jul 12;7(8):2251-2279. doi: 10.1021/acsptsci.4c00250. eCollection 2024 Aug 9.
9
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.基于转化模型的证据表明,在非小细胞肺癌中,标准治疗药物与抗 microRNA-155 联合使用可提高疗效。
Mol Cancer. 2024 Aug 2;23(1):156. doi: 10.1186/s12943-024-02060-5.
10
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.基于转化模型的证据表明,标准治疗药物与抗微小RNA-155联合使用可提高非小细胞肺癌的疗效。
medRxiv. 2024 Mar 15:2024.03.14.24304306. doi: 10.1101/2024.03.14.24304306.

本文引用的文献

1
Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1).临床前和临床证据表明,恶唑烷酮类抗生素通过有机阴离子转运蛋白 3(OAT3/SLC22A8)和多药和毒素外排蛋白 1(MATE1/SLC47A1)协同转运和肾脏分泌。
J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44. doi: 10.1124/jpet.110.170753. Epub 2010 Jun 2.
2
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited.预测治疗性蛋白的人体清除率:重新探讨简单的体表面积比例法。
Biopharm Drug Dispos. 2010 May;31(4):253-63. doi: 10.1002/bdd.708.
3
Body size and metabolic rate.身体大小与代谢率。
Physiol Rev. 1947 Oct;27(4):511-41. doi: 10.1152/physrev.1947.27.4.511.
4
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.I 型干扰素的受体介导的药代动力学和药效学的种间缩放。
Pharm Res. 2010 May;27(5):920-32. doi: 10.1007/s11095-010-0098-6. Epub 2010 Mar 16.
5
Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.抗白细胞介素-6 嵌合单克隆抗体(西妥昔单抗)在转移性肾细胞癌患者中的药代动力学和药效学建模。
Clin Cancer Res. 2010 Mar 1;16(5):1652-61. doi: 10.1158/1078-0432.CCR-09-2581. Epub 2010 Feb 23.
6
Interspecies scaling of therapeutic monoclonal antibodies: initial look.治疗性单克隆抗体的种间缩放:初步观察。
J Clin Pharmacol. 2009 Dec;49(12):1382-402. doi: 10.1177/0091270009337134. Epub 2009 Oct 16.
7
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.生物技术药物的药代动力学:肽、蛋白质和单克隆抗体。
Curr Drug Metab. 2009 Sep;10(7):661-91. doi: 10.2174/138920009789895499.
8
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.使用生物荧光成像比较赛妥珠单抗聚乙二醇化制剂、阿达木单抗和英夫利昔单抗在胶原诱导性关节炎小鼠炎症爪子中的分布。
J Immunol Methods. 2009 Aug 31;348(1-2):36-41. doi: 10.1016/j.jim.2009.06.009. Epub 2009 Jun 28.
9
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.人源化抗CD20抗体veltuzumab治疗难治性/复发性非霍奇金淋巴瘤:I/II期研究结果
J Clin Oncol. 2009 Jul 10;27(20):3346-53. doi: 10.1200/JCO.2008.19.9117. Epub 2009 May 18.
10
Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept.将固定指数0.75应用于人体药物清除率预测:一个不准确且具有误导性的概念。
Drug Metabol Drug Interact. 2009;24(1):57-81. doi: 10.1515/dmdi.2009.24.1.57.

种间尺度转换与人体清除率预测:小分子药物与大分子药物的比较

Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

作者信息

Huh Yeamin, Smith David E, Feng Meihau Rose

机构信息

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

Xenobiotica. 2011 Nov;41(11):972-87. doi: 10.3109/00498254.2011.598582. Epub 2011 Sep 5.

DOI:10.3109/00498254.2011.598582
PMID:21892879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4181675/
Abstract

Human clearance prediction for small- and macro-molecule drugs was evaluated and compared using various scaling methods and statistical analysis. Human clearance is generally well predicted using single or multiple species simple allometry for macro- and small-molecule drugs excreted renally. The prediction error is higher for hepatically eliminated small-molecules using single or multiple species simple allometry scaling, and it appears that the prediction error is mainly associated with drugs with low hepatic extraction ratio (Eh). The error in human clearance prediction for hepatically eliminated small-molecules was reduced using scaling methods with a correction of maximum life span (MLP) or brain weight (BRW). Human clearance of both small- and macro-molecule drugs is well predicted using the monkey liver blood flow method. Predictions using liver blood flow from other species did not work as well, especially for the small-molecule drugs.

摘要

使用各种缩放方法和统计分析对小分子和大分子药物的人体清除率预测进行了评估和比较。对于经肾脏排泄的大分子和小分子药物,使用单物种或多物种简单异速生长法通常能很好地预测人体清除率。对于经肝脏消除的小分子药物,使用单物种或多物种简单异速生长缩放法时预测误差较高,并且似乎预测误差主要与肝脏提取率(Eh)低的药物有关。使用校正了最大寿命(MLP)或脑重量(BRW)的缩放方法可降低经肝脏消除的小分子药物人体清除率预测中的误差。使用猴肝血流量法能很好地预测小分子和大分子药物的人体清除率。使用其他物种的肝血流量进行的预测效果不佳,尤其是对于小分子药物。